DVAX
Price
$12.41
Change
+$0.04 (+0.32%)
Updated
Mar 27, 6:59 PM EST
35 days until earnings call
TEVA
Price
$14.44
Change
+$0.29 (+2.05%)
Updated
Mar 27, 6:59 PM EST
34 days until earnings call
Ad is loading...

Compare predictions DVAX vs TEVA

Header iconDVAX vs TEVA Comparison
Open Charts DVAX vs TEVABanner chart's image
Dynavax Technologies
Price$12.41
Change+$0.04 (+0.32%)
Volume$486.59K
CapitalizationN/A
Teva Pharmaceutical Industries
Price$14.44
Change+$0.29 (+2.05%)
Volume$5.88M
CapitalizationN/A
View a ticker or compare two or three
DVAX vs TEVA Comparison Chart

Loading...

DVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
TEVADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
DVAX vs. TEVA commentary
Mar 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a StrongBuy and TEVA is a Hold.

COMPARISON
Comparison
Mar 28, 2024
Stock price -- (DVAX: $12.41 vs. TEVA: $14.43)
Brand notoriety: DVAX: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DVAX: 49% vs. TEVA: 107%
Market capitalization -- DVAX: $1.62B vs. TEVA: $16.13B
DVAX [@Pharmaceuticals: Other] is valued at $1.62B. TEVA’s [@Pharmaceuticals: Other] market capitalization is $16.13B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.16B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 1 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • DVAX’s FA Score: 1 green, 4 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).

  • DVAX’s TA Score: 5 bullish, 4 bearish.
  • TEVA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DVAX is a better buy in the short-term than TEVA.

Price Growth

DVAX (@Pharmaceuticals: Other) experienced а +2.56% price change this week, while TEVA (@Pharmaceuticals: Other) price change was +7.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +8.45%. For the same industry, the average monthly price growth was +5.30%, and the average quarterly price growth was +13.33%.

Reported Earning Dates

DVAX is expected to report earnings on May 02, 2024.

TEVA is expected to report earnings on May 01, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+8.45% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for DVAX with price predictions.
OPEN
A.I.dvisor published
a Summary for TEVA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
TEVA($16.1B) has a higher market cap than DVAX($1.62B). DVAX has higher P/E ratio than TEVA: DVAX (31.63) vs TEVA (22.62). TEVA YTD gains are higher at: 38.218 vs. DVAX (-11.230). TEVA has higher annual earnings (EBITDA): 1.56B vs. DVAX (9.67M). TEVA has more cash in the bank: 3.23B vs. DVAX (742M). DVAX has less debt than TEVA: DVAX (257M) vs TEVA (20.2B). TEVA has higher revenues than DVAX: TEVA (15.8B) vs DVAX (232M).
DVAXTEVADVAX / TEVA
Capitalization1.62B16.1B10%
EBITDA9.67M1.56B1%
Gain YTD-11.23038.218-29%
P/E Ratio31.6322.62140%
Revenue232M15.8B1%
Total Cash742M3.23B23%
Total Debt257M20.2B1%
FUNDAMENTALS RATINGS
DVAX vs TEVA: Fundamental Ratings
DVAX
TEVA
OUTLOOK RATING
1..100
920
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
9092
PRICE GROWTH RATING
1..100
6138
P/E GROWTH RATING
1..100
420
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (67) in the Biotechnology industry is in the same range as TEVA (81) in the Pharmaceuticals Generic industry. This means that DVAX’s stock grew similarly to TEVA’s over the last 12 months.

DVAX's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for TEVA (100) in the Pharmaceuticals Generic industry. This means that DVAX’s stock grew somewhat faster than TEVA’s over the last 12 months.

DVAX's SMR Rating (90) in the Biotechnology industry is in the same range as TEVA (92) in the Pharmaceuticals Generic industry. This means that DVAX’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Price Growth Rating (38) in the Pharmaceuticals Generic industry is in the same range as DVAX (61) in the Biotechnology industry. This means that TEVA’s stock grew similarly to DVAX’s over the last 12 months.

DVAX's P/E Growth Rating (4) in the Biotechnology industry is in the same range as TEVA (20) in the Pharmaceuticals Generic industry. This means that DVAX’s stock grew similarly to TEVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXTEVA
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
63%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 14 days ago
83%
Bearish Trend 10 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
70%
View a ticker or compare two or three
Ad is loading...
DVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
TEVADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IASCX13.620.26
+1.95%
Voya Small Company Port A
CVTRX45.730.29
+0.64%
Calamos Growth & Income A
BAFFX38.820.22
+0.57%
Brown Advisory Flexible Equity Inst
HAICX9.070.05
+0.55%
Hartford AARP Balanced Retirement C
RGBEX37.480.20
+0.54%
American Funds Global Balanced R4

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.32%
ACET - DVAX
39%
Loosely correlated
+3.57%
SNDL - DVAX
35%
Loosely correlated
+10.66%
AMPH - DVAX
28%
Poorly correlated
+0.65%
PETQ - DVAX
27%
Poorly correlated
-1.97%
DCPH - DVAX
27%
Poorly correlated
+2.50%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with VTRS. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
+2.05%
VTRS - TEVA
36%
Loosely correlated
+1.98%
ELAN - TEVA
32%
Poorly correlated
+1.76%
EGRX - TEVA
30%
Poorly correlated
-0.60%
PRGO - TEVA
29%
Poorly correlated
+2.14%
PAHC - TEVA
27%
Poorly correlated
+1.95%
More